| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(6 years from now) | |
Tekamlo is owned by Novartis.
Tekamlo contains Aliskiren Hemifumarate; Amlodipine Besylate.
Tekamlo has a total of 1 drug patent out of which 0 drug patents have expired.
Tekamlo was authorised for market use on 26 August, 2010.
Tekamlo is available in tablet;oral dosage forms.
The generics of Tekamlo are possible to be released after 21 December, 2029.
Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 26 August, 2010
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
TEKAMLO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic